爪蟾驱动蛋白样蛋白2靶蛋白在肝细胞癌的表达及临床预后的意义

doi:10.16098/j.issn.0529-1356.2023.04.009

摘要/Abstract

摘要：

目的分析爪蟾驱动蛋白样蛋白2靶蛋白（TPX2）在肝细胞癌(HCC)的表达及其临床预后的意义。方法首先，分别利用UALCAN、K-M Plot以及HPA数据库分析TPX2在HCC的表达水平、生存预后及其相关性；再次，利用TIMER、GEPIA和SangerBox数据库分析TPX2的免疫细胞浸润以及与TP53突变相关性和突变景观图；最后，通过HCCDB数据库分析在HCC中TPX2的共表达基因及其预后价值，并对共表达基因进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析。结果 TPX2在HCC高表达且不利于患者的总体生存（OS）、疾病特异性生存（DSS）、无进展生存（PFS）和无复发生存（RFS）；同时，TPX2在HCC组织与肿瘤细胞纯度和多种免疫细胞（B细胞、CD4⁺T以及 CD8⁺T等）显著相关；并且，TPX2在HCC中的表达水平与TP53突变显著相关。TPX2对HCC患者1年、3年和5年OS预后诊断的受试者工作特征（ROC）曲线下面积（AUC）分别是0.73，95% CI（0.669~0.79）、0.668，95% CI（0.604~0.732）和0.654，95% CI（0.574~0.734）。TPX2的共表达基因在HCC均不利于患者的OS；其GO功能主要富集在有丝分裂与核分裂、微管细胞骨架以及微管运动等，KEGG主要富集在细胞周期、卵母细胞减数分裂以及p53信号等通路上，且对HCC患者1年、3年和5年OS预后诊断的ROC曲线下面积AUC分别是0.801，95% CI（0.745~0.856）、0.725，95% CI（0.667~0.786）和0.711，95% CI（0.635~0.788）。结论 TPX2与HCC的发生密切相关，不利于HCC患者的生存预后，可作为HCC诊断与预后的生物标志物。

关键词: 爪蟾驱动蛋白样蛋白2靶蛋白, 无病生存, 肝细胞癌, 生物信息学, 数据库分析

Abstract:

Objective To analyze the expression of targeting protein for xenopus kinesin-like protein 2(TPX2) in hepatocellular carcinoma (HCC) and its clinical prognostic significance. Methods First, the expression levels, survival prognosis and correlation of TPX2 in HCC were analyzed using UALCAN, K-PLOT and HPA databases. Secondly, the TIMER, GEPIA, and SangerBox databases were used to analyze the immune cell infiltration of TPX2, its correlation with TP53 mutation, and the mutation landscape map. Finally, the co-expressed genes of TPX2 in HCC and their prognostic value were analyzed by HCCDB database, and the co-expressed genes were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) were analyzed by the HCCDB database. Results TPX2 was highly expressed in HCC and was not conducive to overall survival(OS), disease-specific survival(DSS), progression-free survival(PFS), and recurrence free survival(RFS) of HCC patients; and its presence in HCC was significantly correlated with tumor cell purity and multiple immune cells (B cells, CD4⁺T, and CD8⁺T, etc.); Furthermore, the expression level of TPX2 in HCC was significantly correlated with TP53 mutation. The area under curve(AUC) under receiver operating characteristic(ROC) curve of TPX2 for the 1-year, 3-year and 5-year OS prognostic diagnosis in HCC patients was 0.73, 95% CI (0.669-0.79), 0.668, 95% CI (0.604-0.732) and 0.654,5% CI (0.574-0.734), respectively. Co-expressed genes of TPX2 were not conducive to OS of patient; its GO function was mainly enriched in mitosis and nuclear division, microtubule cytoskeleton, and KEGG was mainly enriched in cell cycle, oocyte meiosis and p53 signaling pathways, and AUC of the 1-year, 3-year and 5-year OS prognostic for HCC patients was 0.801, 95% CI (0.745-0.856), 0.725, 95% CI (0.667-0.786) and 0.711, 95% CI (0.635~0.788). Conclusion TPX2 is closely related to the occurrence of HCC, which is not conducive to the survival and prognosis of HCC patients, and can be served as a biomarker for the diagnosis and prognosis of HCC.

Key words:

Targeting protein for xenopus kinesin-like protein 2, Disease-free survival, Hepatocellular carcinoma, Bioinformatics, Database analysis

中图分类号:

R365

AN Shao-guang MA Jun-jie ZANG Hao-xuan LU Jin. 爪蟾驱动蛋白样蛋白2靶蛋白在肝细胞癌的表达及临床预后的意义[J]. 解剖学报, 2023, 54(4): 434-444.

参考文献

［1］King MR, Petry S. Phase separation of TPX2 enhances and spatially coordinates microtubule nucleation［J］. Nat Commun, 2020, 11(1): 270.

［2］Song T, Xu A, Zhang Z, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075［J］. J Cell Physiol, 2019, 234(8): 14296-14305.

［3］Taherdangkoo K, Kazemi Nezhad SR, Hajjari MR, et al. miR-485-3p suppresses colorectal cancer via targeting TPX2［J］. Bratisl Lek Listy, 2020, 121(4): 302-307.

［4］Tomii C, Inokuchi M, Takagi Y, et al. TPX2 expression is associated with poor survival in gastric cancer［J］. World J Surg Oncol, 2017, 15(1): 14.

［5］Lu XH, Yu P, Tao H, et al. Correlation between TOP2A gene expression and the number of CD4+ T cells in hepatocellular carcinoma and its clinical prognostic significance ［J］. Cell and Molecular Immunology Journal, 2022, 38(1): 24-31. (in Chinese)

卢兴浩,俞鹏,陶恒,等.拓扑异构酶Ⅱα(TOP2A)基因的表达与CD4+ T细胞在肝细胞癌中的数量相关性及临床预后意义［J］.细胞与分子免疫学杂志, 2022, 38(1): 24-31.

［6］Tan YL, Dai ZW, Tang B. Abnormal expression of glypican-3 and ubiquitin D in hepatocellular carcinoma and the associated interaction［J］. Acta Anatomica Sinica, 2021, 52(5): 744-750. (in Chinese)

谭玉靓,戴姿薇,唐标.磷脂酰肌醇蛋白聚糖3和泛素D基因在肝细胞癌中的异常表达及其相互作用［J］.解剖学报, 2021, 52(5): 744-750.

［7］Sun Q, Yao GD, Song XY, et al. Autophagy antagonizes apoptosis induced by flavan enantiomers from Daphne giraldii in hepatic carcinoma cells in vitro［J］. Eur J Med Chem, 2017, 133: 1-10.

［8］Liu M, Zeng Y, Zhu ShSh, et al. Protein kinase CβⅡ promoting the development of hepatocellular carcinoma via inducing epithelial-mesenchymal transition and angiogenesis［J］. Acta Anatomica Sinica, 2020, 51 (6): 912-918. (in Chinese)

刘敏,曾云,祝珊珊,等.蛋白激酶CβⅡ诱导上皮-间质转化及血管新生促进肝癌发展［J］.解剖学报, 2020, 51(6): 912-918.

［9］Wei JH, Zhang ZC, Wynn RM, et al. GM130 regulates golgi-derived spindle assembly by activating TPX2 and capturing microtubules［J］. Cell, 2015, 162(2): 287-299.

［10］Moss DK, Wilde A, Lane JD. Dynamic release of nuclear RanGTP triggers TPX2-dependent microtubule assembly during the apoptotic execution phase［J］. J Cell Sci, 2009, 122(Pt 5): 644-655.

［11］Yang ZhX, Huang ZhA, Pan LH, et al. Effects of TPX2 on proliferation, apoptosis and cleaved caspase-3 expression of human lung cancer cells［J］. Chinese Journal of Anatomy and Clinics Medicine, 2018, 23(2): 155-159. (in Chinese)

杨忠信,黄志昂,潘丽红,等.TPX2对人肺癌细胞增殖、凋亡及cleavedcaspase-3表达的影响［J］.中华解剖与临床杂志, 2018, 23(2): 155-159.

［12］Koike Y, Yin C, Sato Y, et al. TPX2 is a prognostic marker and promotes cell proliferation in neuroblastoma［J］. Oncol Lett, 2022, 23(4): 136.

［13］Kahl I, Mense J, Finke C, et al. The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients［J］. J Cell Biochem, 2022, 123(3): 581-600.

［14］Wang J, Zheng H, He H, et al. TPX2 Serves as a cancer susceptibility gene and is closely associated with the poor prognosis of endometrial cancer［J］. Genet Res (Camb), 2022, 2022: 5401106.

［15］Sui C, Song Z, Yu H, et al. Prognostic significance of TPX2 and NIBP in esophageal cancer［J］. Oncol Lett, 2019, 18(4): 4221-4229.

［16］Zhu H, Liu J, Feng J, et al. Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer［J］. Medicine (Baltimore), 2020, 99(49): e23554.

［17］Wang X, Wang J, Shen H, et al. Downregulation of TPX2 impairs the antitumor activity of CD8+T cells in hepatocellular carcinoma［J］. Cell Death Dis, 2022, 13(3): 223.

［18］Ye JM, Su B, Li YQ, et al. Expression of protein TPX2 in small cell lung cancer and its prognostic significance ［J］. Chronic Pathematology Journal, 2017, 18 (2): 127-130. (in Chinese)

叶静梅,苏彬,李翊泉,等.小细胞肺癌组织中TPX2蛋白的表达及其临床意义［J］.慢性病学杂志, 2017, 18(2): 127-130.

［19］ Matson DR, Denu RA, Zasadil LM, et al. High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability［J］. BMC Cancer, 2021, 21(1): 186.

[20］Hsu CW, Chen YC, Su HH, et al. Targeting TPX2 suppresses the tumorigenesis of hepatocellular carcinoma cells resulting in arrested mitotic phase progression and increased genomic instability［J］. J Cancer, 2017, 8(8): 1378-1394.

［21］Huang DH, Jian J, Li S, et al. TPX2 silencing exerts anti-tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway［J］. Int J Mol Med, 2019, 44(6): 2113-2122.

［22］Yao H, Su S, Xia D, et al. F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway［J］. Biomed Pharmacother, 2018, 107:1712-1719.

［23］Zou Z, Zheng B, Li J, et al. TPX2 level correlates with cholangiocarcinoma cell proliferation, apoptosis, and EMT［J］. Biomed Pharmacother, 2018, 107: 1286-1293.

［24］Neumayer G, Belzil C, Gruss OJ, et al. TPX2: of spindle assembly, DNA damage response, and cancer［J］. Cell Mol Life Sci, 2014, 71(16): 3027-3047.

［25］Takahashi Y, Sheridan P, Niida A, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC［J］. Ann Oncol, 2015, 26(5): 935-942.

[1]	于华婧魏路阳刘姗姗管成剑张忠涛. MLLT1超伸长复合亚基在肝细胞癌发生发展中的作用及其临床意义[J]. 解剖学报, 2023, 54(4): 425-433.
[2]	李晓军张雅敏. 通过生物信息学分析寻找影响结肠癌患者预后的铁死亡相关基因[J]. 解剖学报, 2023, 54(4): 445-452.
[3]	管成剑于华婧张小东饶全张伟涛刘坤吴鸿伟汪栋张忠涛郭伟. 基于癌症多组学数据库深度解析磷酸甘油激酶1在肝细胞癌中的表达及临床意义[J]. 解剖学报, 2022, 53(6): 744-753.
[4]	向丽莼姜钟翔姜小叶陈雪诺姜政. Epsin3在结直肠癌中的差异表达及生物信息学分析[J]. 解剖学报, 2022, 53(4): 507-514.
[5]	李永涛姜杨孙石柱王璐璐刘丹阳刘娜张晓东沈雷. 基于网络药理学探讨趋化因子-13对间充质干细胞增殖和迁移的影响[J]. 解剖学报, 2021, 52(6): 889-900.
[6]	谭玉靓戴姿薇唐标. 磷脂酰肌醇蛋白聚糖3和泛素D基因在肝细胞癌中的异常表达及其相互作用[J]. 解剖学报, 2021, 52(5): 744-750.
[7]	赵雪莹司丽娜魏萌乔跃兵杨松鹤程露阳 . 侧脑室注射促性腺激素抑制激素/RF酰胺相关肽-3对卵巢摘除术后补充雌激素大鼠子宫腔液影响的蛋白质组学分析[J]. 解剖学报, 2021, 52(4): 499-505.
[8]	刘发煇侯婉云梁家东徐晶晶罗春英. 唾液腺腺样囊性癌中相关微小RNAs及其靶基因的生物信息学分析[J]. 解剖学报, 2021, 52(4): 601-608.
[9]	史卓李家慧高静董艳莉任甫文普帅 . 小鼠心肌肥厚枢纽基因的筛选与鉴定[J]. 解剖学报, 2021, 52(3): 391-397.
[10]	陈小龙万亚锋黄平. 基于质粒的蛋白激酶B1特异性小干扰RNA和P53共表达协同抑制肝细胞癌细胞的增殖、迁移和侵袭[J]. 解剖学报, 2021, 52(2): 251-257.
[11]	刘敏曾云祝珊珊巫佳翠高洪泉伊雪. 蛋白激酶CβⅡ诱导上皮-间质转化及血管新生促进肝癌发展[J]. 解剖学报, 2020, 51(6): 912-918.
[12]	马战姜钟翔姜政. PHLDA2对肝癌细胞的增殖、侵袭、迁移和凋亡的影响[J]. 解剖学报, 2020, 51(3): 398-404.
[13]	刘中娇窦龙涛庄振刘玲周永维刘曼李晶张红梅. 乳头状甲状腺癌差异表达基因的筛选及生存分析[J]. 解剖学报, 2020, 51(1): 51-57.
[14]	秦松林周洋胡威刘伯龙唐正. 膀胱癌基因芯片生物信息分析及功能探讨[J]. 解剖学报, 2019, 50(3): 310-316.
[15]	许优沁张庆芬张超. 人外周血细胞放射损伤相关基因的生物信息学[J]. 解剖学报, 2017, 48(1): 37-42.